Daiichi Sankyo Addresses Healthcare Gaps and Unmet Needs in Cardiovascular Care
Daiichi Sankyo Europe (Daiichi Sankyo) has announced an enhanced commitment to tackling significant gaps in cardiovascular care, focusing on disparities in treatment and outcomes among different patient groups. This renewed focus follows the presentation of data from sub-analyses of the…
Phase 3 CAMZYOS® (mavacamten) Study Confirms Efficacy and Safety for Obstructive Hypertrophic Cardiomyopathy
Bristol Myers Squibb (NYSE: BMY) has announced new long-term follow-up data from the EXPLORER-LTE cohort of the MAVA-Long-Term Extension (LTE) study. This data evaluates the efficacy and safety of CAMZYOS® (mavacamten) in adults with New York Heart Association (NYHA) class…
Sensorion to Lead Hearing Loss Symposium at World Congress of Audiology 2024 in Paris
Sensorion (FR0012596468 – ALSEN), a leading clinical-stage biotechnology company focused on innovative therapies for hearing loss, has announced its participation in the 36th World Congress of Audiology (WCA) in Paris from September 19-22, 2024. The company will host a symposium…
EDX Medical Partners with Caris Life Sciences for Molecular Profiling Distribution in UK and Nordic Countries
EDX Medical Group plc, a company focused on innovative digital diagnostics for personalized treatment in cancer, heart disease, and infectious diseases, has signed a distribution agreement with Caris Life Sciences®. Caris, a U.S.-based leader in next-generation AI TechBio and precision…
Arrowhead Presents Phase 3 PALISADE Study Data on Plozasiran at ESC 2024
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today the results of the Phase 3 PALISADE study evaluating investigational plozasiran in patients with familial chylomicronemia syndrome (FCS), a rare and severe genetic condition with no approved treatments in the U.S. The study…
Fresenius Kabi and AABB Launch 19th Annual Blood Collectors Week
Fresenius Kabi and the Association for the Advancement of Blood & Biotherapies (AABB) have announced the start of the 19th annual Blood Collectors Week, taking place from September 1 to September 7, 2024. This week celebrates the dedicated professionals who…
ESC 2024: INFINITY-SWEDEHEART Trial Confirms DynamX Bioadaptor Success
Elixir Medical, a developer of innovative cardiovascular technologies, announced that the INFINITY-SWEDEHEART Randomized Controlled Trial (RCT) has met its primary endpoint. The trial compared the novel DynamX® Coronary Bioadaptor System with the Resolute Onyx™ zotarolimus drug-eluting stent (DES), showing non-inferiority…
Daiichi Sankyo Highlights Gaps in Cardiovascular Care
Daiichi Sankyo Europe today reaffirmed its dedication to tackling unmet needs and barriers in cardiovascular care by highlighting treatment disparities and outcomes among different patient groups. This announcement coincides with the presentation of new data from sub-analyses of the SANTORINI…
Updated Flu and COVID-19 Shots Now at CVS Pharmacy® and MinuteClinic®
CVS Pharmacy® (NYSE: CVS) has announced that the updated 2024-2025 flu and COVID-19 vaccines are now available at CVS Pharmacy and MinuteClinic® locations nationwide. Patients can walk in for a vaccination or use the updated digital scheduler to book an…
UnitedHealthcare Grants $114,500 to Seven Iowa Organizations for Social Drivers of Health
UnitedHealthcare has awarded $114,500 to seven Iowa organizations to enhance health outcomes by addressing social determinants of health. This funding aligns with UnitedHealthcare’s goal to positively impact underserved communities and improve access to essential resources. Marsha Connor, CEO of UnitedHealthcare…
Collaborative Bridges Selects HealthEC for Behavioral Health Care Coordination
Collaborative Bridges, a network of West Side Chicago safety net hospitals and mental health agencies, has selected HealthEC’s data and analytics solution to enhance care coordination for behavioral health patients. HealthEC’s technology will integrate Electronic Health Records and workflows, ensuring…
OS Therapies Completes OST-HER2 Phase 2b Trial Enrollment and Final Treatment Dose
OS Therapies Incorporated (NYSE American: OSTX) announced today that the last patient (Patient #41) in the AOST-2121 clinical trial of OST-HER2 for recurrent, resected Osteosarcoma has received their final treatment dose. This patient is expected to complete the final radiological…